SNDX
USDSyndax Pharmaceuticals Inc. Common Stock
Prix en Temps Réel
Graphique des Prix
Métriques Clés
Métriques de Marché
Ouverture
$13.600
Haut
$15.799
Bas
$13.150
Volume
3.36M
Fondamentaux de l'Entreprise
Capitalisation Boursière
1.3B
Industrie
Biotechnologie
Pays
United States
Statistiques de Trading
Volume Moyen
2.67M
Bourse
NMS
Devise
USD
Intervalle sur 52 Semaines
Actualités Connexes
UBS Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $38
UBS analyst David Dai maintains Syndax Pharmaceuticals with a Buy and raises the price target from $35 to $38.
Barclays Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $22
Barclays analyst Peter Lawson maintains Syndax Pharmaceuticals with a Overweight and raises the price target from $19 to $22.
Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025
– 12 revumenib and 11 axatilimab abstracts accepted, including 6 oral presentations, underscoring Syndax's leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in
Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will host an
Syndax Announces Participation in November Investor Conferences
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief
Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals with a Buy and maintains $40 price target.
Actions Connexes
SRCL
Stericycle Inc.
MSTR
MicroStrategy Incorporated
AGM
Federal Agricultural Mortgage Corporation
CLGN
CollPlant Biotechnologies Ltd Ordinary Shares
WEA
Western Asset Bond Fund Share of Beneficial Interest
Restez Informé
Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.